NCT01219751

Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma

Detailed description

There have been no standard treatment in non-clear cell renal cell carcinoma. Retrospective studies showed sunitinib or sorafenib might be active in non-clear cell renal cell carcinoma, especially papillary type and chromophobe type. This study is to evaluate efficacy and safety of sunitinib in this group of patients.

Conditions

• Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Sunitinib	Sunitinib 50 mg D1-D28 every 6 weeks

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-10-13
• Last updated: 2011-06-17

Locations

1 site across 1 country: South Korea